Donate
Suivez-nous sur Linked In
Suivez-nous sur Youtube

Where oncology and autoimmunity converge to accelerate
immunotherapies. CAR‑T cells, Bispecific antibodies, Immune Checkpoint Inhibitors drive Innovations for Patients.
One ambitious objective: to cure autoimmune diseases.

Decoding autoimmunity–cancer crosstalk to enable
curative immunotherapies.

Our Research Targets

INNOVATE

Developing
next-generation
Tools for Experimental
and Clinical
Immunotherapies

Understand

Decoding common
and opposite immune
regulation mechanisms
in Cancer and
Autoimmune Diseases

Treat

Clinical Trials
to test CAR-T
and Bispecific
Antibody Strategies

Teach

Advancing
Education
and Training in
Immunotherapies

Now, CAR‑T cells and Bispecific Therapies offer unprecedented hope with patients achieving lasting remission beyond two years.
FHU CARE² is pioneering this new frontier toward curative immunotherapies.

Prof. Xavier Mariette

“Our goal with FHU CARE²
is clear: transform scientific
knowledge into curative,
patient-centered
immunotherapies through
strong scientific
and clinical synergy.”

See on

Dr. Samuel Bitoun

“FHU CARE² opens a new
chapter at the crossroads
of cancer and autoimmunity —
connecting expertise
to drive real clinical
breakthroughs.”

See on

Dr. Camille Bigenwald

“With FHU CARE²,
we harness the power
of CAR T and Bispecific
Therapies to turn scientific
innovation into lasting
remission.”

Led by Samuel Bitoun, Camille Bigenwald and Xavier Mariette, FHU CARE²
federates clinicians, researchers, teachers and industry partners
across rheumatology, internal medicine, haematology,
nephrology, gastroenterology, neurology and haemato‑oncology
(AP-HP, Université Paris-Saclay, Inserm, Gustave Roussy, CEA, INRAE)
to drive translational excellence in immunotherapies.

Our latest publications

A specific molecular profiling of secreted rheumatoid factors in Sjögren's disease patients with lymphoma

Jing Jing Wang, Alexander Troelnikov, Bridie Armour, Caizhu Teng, Tim Chataway, Véronique le Guern, Eric Hachulla, Valérie Devauchelle-Pensec, Claire Larroche, Jacques-Eric Gottenberg, Xavier Mariette, Gaetane Nocturne

Rheumatology (Oxford) | 2026 Oct 1;65(10):keag509. doi: 10.1093/rheumatology/keag509.

Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies

Jérôme Avouac 1, Maurine Jouret 2, Samuel Bitoun 3, Raphaël Borie 4, Divi Cornec 5, Valérie Devauchelle-Pensec 5, Philippe Dieude 6, Bruno Fautrel 7, Jacques-Eric Gottenberg 8, Pierre-Antoine Juge 6, Jean Guillaume Letarouilly 9, Sophie Hecquet 10, Yves-Marie Pers 11, Christophe Richez 12, Adeline Ruyssen-Witrand 13, Adrien Schvartz 14, Raphaèle Seror 3, Marc Scherlinger 8; Club for Innovative Immunotherapies in Immune-mediated Inflammatory Diseases

Lancet Rheumatol . | 2026 Nov;8(11):e908-e920. doi: 10.1016/S2665-9913(26)00184-0.

See all Publications